HEPARIN SODIUM | N017036 | BAXTER HEALTHCARE CORP
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Active | Boston Scientific Corporation | 544 | 2021-08-02 → 2026-08 | |
| N/A | Active | Beijing Tiantan Hospital | 224 | 2024-12-24 → 2029-08 | |
| N/A | Active | NYU Langone Health | 206 | 2018-06-29 → 2026-06-30 | |
| N/A | Active | University of Colorado, Denver | 84 | 2016-06 → 2026-12-11 | |
| N/A | Not Yet Recruiting | 3W-Research Collaboration Group | 62 | 2026-10-01 → 2030-01-01 | |
| Phase 4 | Not Yet Recruiting | Allied Hospital Faisalabad | 100 | 2026-06 → 2026-11 | |
| N/A | Recruiting | Mayo Clinic | 60 | 2024-09-15 → 2027-09-01 | |
| N/A | Recruiting | Université de Sherbrooke | 16 | 2019-12-09 → 2027-03-30 | |
| Phase 2 | Recruiting | Stanford University | 50 | 2025-04-15 → 2029-09 | |
| Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2,000 | 2026-07-09 → 2031-07-09 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
20 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.